Table 9.
List of studies on the side effects following COVID-19 vaccination in Arab countries.
| Country | Population | Sample Size | Vaccines (%) | Reference |
|---|---|---|---|---|
| Iraq | General population | 1012 | AstraZeneca (60.1) Pfizer-BioNTech (29.2) Sinopharm (10.7) |
[77] |
| Jordan | General population | 2213 | Sinopharm (38.2) AstraZeneca (31) Pfizer-BioNTech (27.3) Sputnik V (2.9) Moderna, Coaxin, and Johnson & Johnson (0.6) |
[13] |
| Jordan | General population | 1086 | Sinopharm (26.4) | [78] |
| Jordan | General population | 1004 | Sinopharm (51.1) Pfizer-BioNTech (48.9) |
[79] |
| Jordan | Healthcare workers | 409 | AstraZeneca (43.8) Pfizer-BioNTech (34.5) Sinopharm (21.8) |
[80] |
| Kuwait | People with epilepsy | 82 | Pfizer-BioNTech (62) AstraZeneca (38) |
[81] |
| Oman | General population | 753 | AstraZeneca (78) Pfizer-BioNTech (22) |
[82] |
| Saudi Arabia | General population | 18,543 | AstraZeneca (97.8) Pfizer-BioNTech (2.3) |
[83] |
| Saudi Arabia | General population | 4170 | Pfizer-BioNTech (61) AstraZeneca (39) |
[84] |
| Saudi Arabia | General population | 1592 | AstraZeneca | [85] |
| Saudi Arabia | General population | 515 | AstraZeneca (75) Pfizer-BioNTech (25) |
[86] |
| Saudi Arabia | General population | 455 | Pfizer-BioNTech | [87] |
| Saudi Arabia | General population | 330 | AstraZeneca (50.6) Pfizer-BioNTech (49.4) |
[88] |
| UAE | General population | 1080 | Sinopharm | [12] |
UAE, United Arab Emirates.